These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 12115095)

  • 21. A cost-benefit analysis of typhoid fever immunization programmes in an Indian urban slum community.
    Poulos C; Bahl R; Whittington D; Bhan MK; Clemens JD; Acosta CJ
    J Health Popul Nutr; 2004 Sep; 22(3):311-21. PubMed ID: 15609784
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Economic evaluation of the 7-vaccine routine childhood immunization schedule in the United States, 2001.
    Zhou F; Santoli J; Messonnier ML; Yusuf HR; Shefer A; Chu SY; Rodewald L; Harpaz R
    Arch Pediatr Adolesc Med; 2005 Dec; 159(12):1136-44. PubMed ID: 16330737
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness of introducing the conjugated pneumococcal vaccine to routine free immunizations for infants in Lazio, Italy.
    Giorgi-Rossi P; Merito M; Borgia P
    Health Policy; 2009 Feb; 89(2):225-38. PubMed ID: 18639952
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Economic evaluation of vaccination programs in adults].
    Lucioni C
    Ann Ig; 2002; 14(3 Suppl 3):69-73. PubMed ID: 12389413
    [No Abstract]   [Full Text] [Related]  

  • 25. Cost-effectiveness and potential impact of rotavirus vaccination in the United States.
    Widdowson MA; Meltzer MI; Zhang X; Bresee JS; Parashar UD; Glass RI
    Pediatrics; 2007 Apr; 119(4):684-97. PubMed ID: 17403839
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The cost of epidemiological transition: a study of a decrease in pertussis vaccination coverage.
    Girard DZ
    Health Policy; 2005 Nov; 74(3):287-303. PubMed ID: 15951048
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Costs of diarrheal disease and the cost-effectiveness of a rotavirus vaccination program in kyrgyzstan.
    Flem ET; Latipov R; Nurmatov ZS; Xue Y; Kasymbekova KT; Rheingans RD
    J Infect Dis; 2009 Nov; 200 Suppl 1():S195-202. PubMed ID: 19817600
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Economic evaluations of implemented vaccination programmes: key methodological challenges in retrospective analyses.
    Newall AT; Reyes JF; Wood JG; McIntyre P; Menzies R; Beutels P
    Vaccine; 2014 Feb; 32(7):759-65. PubMed ID: 24295806
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Benefits and costs of immunizing children against influenza at school: an economic analysis based on a large-cluster controlled clinical trial.
    Schmier J; Li S; King JC; Nichol K; Mahadevia PJ
    Health Aff (Millwood); 2008; 27(2):w96-104. PubMed ID: 18216044
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The economics of routine childhood hepatitis A immunization in the United States: the impact of herd immunity.
    Armstrong GL; Billah K; Rein DB; Hicks KA; Wirth KE; Bell BP
    Pediatrics; 2007 Jan; 119(1):e22-9. PubMed ID: 17200247
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rotavirus vaccination for Hong Kong children: an economic evaluation from the Hong Kong Government perspective.
    Ho AM; Nelson EA; Walker DG
    Arch Dis Child; 2008 Jan; 93(1):52-8. PubMed ID: 17855438
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Economic analysis of pertussis illness in the Dutch population: implications for current and future vaccination strategies.
    de Greeff SC; Lugnér AK; van den Heuvel DM; Mooi FR; de Melker HE
    Vaccine; 2009 Mar; 27(13):1932-7. PubMed ID: 19368774
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Vaccination--value for money?].
    Wisløff T; Abrahamsen TG; Bergsaker MA; Løvoll Ø; Kristiansen IS
    Tidsskr Nor Laegeforen; 2006 Oct; 126(20):2670-3. PubMed ID: 17057767
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discounting in the evaluation of the cost-effectiveness of a vaccination programme: A critical review.
    Jit M; Mibei W
    Vaccine; 2015 Jul; 33(32):3788-94. PubMed ID: 26144897
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [How to plan travel vaccinations when they are numerous or the traveler is pressed for time?].
    Tessier D
    Bull Soc Pathol Exot; 1997; 90(4):243-4. PubMed ID: 9479461
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Interest in and limitations of economic assessment applied to the evaluation of medical strategies: examples in oncological hematology].
    Moatti JP
    Therapie; 2001; 56(2):135-8. PubMed ID: 11471364
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost effectiveness and patient welfare.
    Prog Clin Biol Res; 1981; 50():155-78. PubMed ID: 6784127
    [No Abstract]   [Full Text] [Related]  

  • 38. Uncertainty and sensitivity analyses of a dynamic economic evaluation model for vaccination programs.
    Duintjer Tebbens RJ; Thompson KM; Hunink MG; Mazzuchi TA; Lewandowski D; Kurowicka D; Cooke RM
    Med Decis Making; 2008; 28(2):182-200. PubMed ID: 18349438
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-benefit considerations of vaccination against ringworm in cattle.
    Gudding R
    Acta Vet Scand Suppl; 1996; 90():67-8. PubMed ID: 8996889
    [No Abstract]   [Full Text] [Related]  

  • 40. Vaccination Programs: Economic and Leadership Considerations.
    Hartigan-Go KY
    Value Health; 2018 Oct; 21(10):1150-1151. PubMed ID: 30314614
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.